DLBCL
Conference Coverage
Chemo-free combo gets high response rate in relapsed or refractory DLBCL
LUGANO, SWITZERLAND – Lenalidomide plus the anti-CD19 antibody tafasitamab was associated with a 60% overall response rate.
News
CAR T-cell therapy less effective in transformed follicular lymphoma
The complete response rate and duration of response were better in patients with follicular lymphoma than in those with transformed follicular...
News
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCL
The researchers said the findings cast doubt on the ability of this CDK inhibitor to be effective in B-cell lymphomas.
News
Intravenous CNS chemo looks best for testicular DLBCL
Intrathecal chemotherapy did not offer a benefit, according to findings from the retrospective analysis of patients with testicular diffuse large...
Conference Coverage
On second thought, lenalidomide does improve DLBCL outcomes
LUGANO, SWITZERLAND – Adding lenalidomide to R-CHOP reduced the risk of diffuse large B-cell lymphoma progression or death by 34% in the ECOG-...
Conference Coverage
R2-CHOP doesn’t improve survival in DLBCL
LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...
News
CNS-directed therapy appears more effective for synDLBCL
Two-year survival rates were superior among patients who received CNS-intensive therapy.
News
Dasatinib shows promise as a control agent for CAR T cells
The tyrosine kinase inhibitor dasatinib was found to transiently inhibit CAR T-cell function in a preclinical study, suggesting applicability as...
Conference Coverage
No benefit with rituximab after first CR in DLBCL
AMSTERDAM – Rituximab maintenance was no better than observation for patients in first complete remission after induction chemotherapy with R-CHOP...
News
Radiation bridging with axi-cel appears safe in DLBCL
At final follow-up, in a case series of 12 patients with relapsed/refractory DLBCL, the best objective response rate was 81.8%, with complete...